Quantcast

Latest Sirolimus Stories

2009-11-01 06:19:03

Treatment reduces risk, but nearly half of patients stop treatment due to side effects Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. "In spite of the life-saving nature of organ transplantation, the need for transplant recipients to continue treatment with drugs that suppress the...

2009-10-27 09:51:12

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism. The rescue, described as "surprisingly complete" by the researchers, was accomplished with rapamycin, a drug known to act on a protein called mTOR whose role involves the production of other proteins. The idea to test this drug's...

2009-10-21 06:30:00

UNION CITY, Calif., Oct. 21 /PRNewswire/ -- MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME). MacuSight is currently advancing Perceiva in a broad Phase 2 clinical program across multiple large...

2009-10-19 17:30:00

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer...

2009-10-16 08:59:00

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors http://www.reportlinker.com/p0154665/Reportlinker-Adds-Competitor-Analysis-PI3K-AKT-mTOR-Inhibitors.html Product description The present Competitive Intelligence Report about PI3K-AKT-mTOR Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting members of...

2009-10-02 08:26:29

Diet boosts mitochondrial function, has implications for humans Flies fed an "anti-Atkins" low protein diet live longer because their mitochondria function better. The research, done at the Buck Institute for Age Research, shows that the molecular mechanisms responsible for the lifespan extension in the flies have important implications for human aging and diseases such as obesity, diabetes and cancer. The findings, which appear in the October 2 edition of Cell, also provide a new level of...

2009-09-30 07:00:00

UNION CITY, Calif., Sept. 30 /PRNewswire/ -- MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product. The company has completed patient enrollment in four ongoing Phase 2 clinical trials of Perceiva and plans to announce data from these studies in the first half of 2010. All four studies are being conducted at...

2009-09-23 14:16:00

SAN FRANCISCO, Sept. 23 /PRNewswire/ -- OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent. Specifically, histological and optical coherence tomography (OCT) data out to 28 days show that the Combo Stent had lower neointimal hyperplasia and stenosis, as well as...

2009-09-21 14:53:38

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss. Results from the RES-ELUTION I Trial on the safety and effectiveness of a new sirolimus-eluting stent in the treatment of coronary artery disease (a single...

2009-09-21 14:30:31

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). The study, "The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter Registry in Asia," compared the safety and efficacy of sirolimus...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related